AF is the most common arrhythmia encountered in clinical practice, particularly among
elderly patients. The prevalence of AF has increased over the past two decades and, with …

Abstract Background In the ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and≥ 2 dose …

Objectives In 2015, French health authorities assigned 'minor added benefit'status (ASMR
IV) to apixaban and 'no added benefit'(ASMR V) status for dabigatran and rivaroxaban as …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Background Warfarin and other vitamin K antagonists are effective at preventing stroke in
patients with atrial fibrillation (AF). A drawback of these agents is their narrow therapeutic …

Abstract Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Wallentin et al1 report post hoc analysis of the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial in which apixaban was …

Atrial fibrillation (AF) is a common cardiac arrhythmia, especially in the elderly population. It
is associated with cardioembolic complications, particularly strokes, resulting in severe …